Since CPT1A is the rate-limiting enzyme in fatty acid β-oxidation, deficiencies or aberrant regulation of this enzyme can lead to a variety of illnesses, including malignancies and metabolic disorders, making it a promising drug target for treatment87. Here, CPT1A is linked to Other metabolic disease.